Finding a resistant needle in a fungal haystack: New SSP-PCR platform from the Xue Lab detects hidden drug resistance in Cryptococcus faster than ever
Review written by: Roshni Kadam
Invasive fungal infections represent a major global health burden. Of the more than 2 million fungal species estimated to exist, only about 300 are known to cause human infection and yet these account for over 1.5 million deaths annually. The WHO has classified several fungal pathogens into a critical priority group, among which Cryptococcus neoformans is a leading cause of morbidity and mortality in immunocompromised individuals, accounting for roughly 15% of HIV-related deaths through cryptococcal meningitis. Treatment options remain limited, making early detection and diagnosis critical for improved patient outcomes. Current cryptococcosis diagnosis relies heavily on capsule antigen detection, which, while rapid, cannot identify mutation-specific resistance or heteroresistance. New diagnostic technologies are therefore needed to detect Cryptococcus heteroresistance directly. Long-term use of the azole-class antifungal fluconazole can drive the emergence of heteroresistance in C. neoformans, contributing to treatment failure even when standard susceptibility testing appears normal. Azole resistance typically arises from overexpression or mutation of the drug target gene, ERG11, and specific single-nucleotide mutations in ERG11 are known to confer high-level resistance. Detecting this heteroresistance which is a rare resistant subpopulation hidden within a majority wild-type population remains a major diagnostic challenge that even molecular methods like conventional PCR and whole-genome sequencing cannot reliably resolve. The Xue Lab, at the Public Health Research Institute (Rutgers University), developed a SuperSelective primer-based PCR (SSP-PCR) platform for the rapid and specific detection of azole resistance-associated single-nucleotide polymorphisms (SNPs).
The unique design of superselective primers enables the detection of mutant targets, of two known azole resistance SNPs in the ERG11gene: A434T (causes high level fluconazole resistance) and G1885A (Causes multi-azole resistance) even in the presence of closely related wild-type sequences. The normal PCR is just one short stretch of DNA that sticks the template. The “SuperSelective” primers have three parts strung together instead:
The anchor sequence is a long, strongly binding piece at the 5′ end. It sticks firmly to the DNA region of interest: mutant or normal just like an ordinary primer. The bridge sequence deliberately does not pair with the template; it loops out into a floppy, single-stranded bubble, so it contributes no binding strength. The foot sequence is a very short stretch sitting right at the mutation site. Its last base is the "interrogating nucleotide," engineered to match the mutant sequence. Because the foot is so short, it binds stably only when the interrogating nucleotide matches the mutant base exactly; on wild-type DNA, that single mismatch is enough to stop the foot from binding, so the polymerase cannot extend the primer. This design lets the primer amplify mutant DNA almost exclusively. As a result, SSP-PCR detected the A434T mutant far earlier than wild-type and could detect a single mutant copy even in the presence of 10⁴ wild-type copies. Taken together, these results position the Xue Lab's SSP-PCR platform as the first application of SuperSelective primer design for detecting azole-resistance mutations in C. neoformans, and the first such assay demonstrated to work in infected tissue, enabling faster detection of heteroresistance than current diagnostic methods.
---
READ MORE:
Pawar S, Xue HH, Wang S, Marras S, Xue C. A SuperSelective primer-based real-time PCR Platform for hypersensitive detection of azole heteroresistance in Cryptococcus neoformans. bioRxiv [Preprint]. 2026 Apr 24:2026.04.23.720376. doi: 10.64898/2026.04.23.720376. PMID: 42079069; PMCID: PMC13131632.
